Medicare coverage in 2026
The Medicare GLP-1 Bridge is live. It runs from July 1, 2026 through December 31, 2027. CMS furnishes Wegovy, Zepbound and Foundayo for a flat $50 a month to Part D beneficiaries who meet clinical criteria (BMI 35+, or BMI 30+ with heart failure with preserved ejection fraction, uncontrolled hypertension or CKD stage 3a+, or BMI 27+ with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease), for weight-management prescriptions only. It runs through December 31, 2027. If you qualify, $50 a month beats every cash program on our chart. Check whether you qualify in four questions → What CMS published and what to do before July 1 →
Medicare Part D coverage of GLP-1 in 2026 depends on which indication applies to you. For the full cost picture, the copay by indication and the cash floor if nothing applies, see the Medicare GLP-1 cost guide:
Without either indication: until July 1, 2026, Medicare does not cover weight-loss-indication GLP-1. From that date, the Medicare GLP-1 Bridge covers it at $50 a month if you meet the clinical criteria above the grid. If you do not qualify for the Bridge either, the realistic options are cash-pay compounded (see cash-pay rankings) or patient assistance through NovoCare or LillyDirect (see every cost-reduction path).
If you have a SURMOUNT-OSA-qualifying sleep apnea diagnosis, that is a third Medicare-eligible pathway for Zepbound as of December 2024. We maintain a Medicare Advantage PA letter template for OSA with the sleep-study documentation requirements and the trial citations. The CV indication template and T2D template are also live.
Federal retirees:if you carry FEHB alongside Medicare, your federal plan covers Wegovy and Zepbound with prior authorization, independent of Medicare’s obesity exclusion. FEHB Blue Cross coverage for Wegovy and Zepbound →
Sarcopenia, muscle loss and fall risk
Rapid weight loss in adults 65+ includes a meaningful share of lean mass. This compounds age-related sarcopenia and can increase fall risk if unaddressed. The article below covers the dose-adjustment, protein-intake, and resistance-training protocols obesity-medicine specialists use to protect muscle during GLP-1 treatment.
Dose strategy for seniors
Most obesity-medicine specialists recommend a lower maintenance dose for adults 65+. Semaglutide 1.0-1.7 mg weekly often produces meaningful weight loss with substantially less appetite suppression and side-effect burden than the approved maximum of 2.4 mg. Tirzepatide 7.5-10 mg weekly is the comparable senior maintenance range vs the 15 mg approved maximum.
Slower titration also matters: every 6-8 weeks instead of every 4 weeks. This reduces GI side effects and allows polypharmacy interactions to be observed before reaching maintenance dose.
Patient-assistance pathways
For fixed-income retirees, the standard cash-pay path may not be affordable. Three pathways worth evaluating:
- NovoCare Wegovy ($149 pill starter, $349 injection) or LillyDirect Zepbound vials ($299-$449/mo)
- State-specific senior pharmaceutical assistance: New York EPIC, New Jersey PAAD/Senior Gold, Pennsylvania PACE/PACENET
- 340B clinic access if you live near an FQHC or safety-net hospital
If you live rural and don’t have broadband
All telehealth programs require email and basic web navigation. For rural senior patients without reliable broadband, the realistic options are: (1) ask a family member to handle the intake on their behalf, or (2) ask your primary-care doctor to prescribe GLP-1 directly at your next in-person visit, with Medicare Part D coverage if the indication applies. Telehealth is built for connected patients; in-person care remains the better path for the rural-senior population.
Top programs for senior patients
Three programs in our chart handle the polypharmacy and clinical-depth concerns common in senior care:
Frequently asked questions
Does Medicare cover Wegovy or Zepbound for weight loss?
Not under the regular Part D benefit: a 2003 statute excludes weight-loss drugs. Two indication-specific paths exist: Wegovy for established cardiovascular disease (since March 2024) and Zepbound for moderate-to-severe obstructive sleep apnea (since December 2024). From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge adds a third path: a flat $50 a month for Wegovy, Zepbound or Foundayo for Part D beneficiaries who meet CMS clinical criteria (weight-management prescriptions only).
What are the cash options for seniors without Medicare coverage?
The oral Wegovy pill runs $299 a month at maintenance doses through NovoCare ($149 at the starter dose) and branded Zepbound vials run $299 to $449 a month through LillyDirect. Cash-pay telehealth programs with compounded semaglutide start at $149 a month. State senior pharmaceutical assistance programs (New York EPIC, New Jersey PAAD, Pennsylvania PACE) can lower costs further. Prices checked every Monday.
Does GLP-1 cause muscle loss in older adults?
In the trials' DXA substudies (SURMOUNT-1, STEP 1), 25 to 40 percent of lost weight was lean mass, and the risk matters more after 65 because baseline muscle mass is lower. Specialists counter it with protein targets, resistance training, slower titration (every 6 to 8 weeks) and a lower maintenance dose: semaglutide 1.0 to 1.7 mg weekly or tirzepatide 7.5 to 10 mg weekly are the common senior maintenance ranges.
